NCT00002635 is a Phase 2 clinical trial of filgrastim in Lymphoma, sponsored by Yale University.

Who is sponsoring NCT00002635?

NCT00002635 is sponsored by Yale University.

What drugs are being tested in NCT00002635?

Interventions in NCT00002635: filgrastim, aminocamptothecin.

Is NCT00002635 still recruiting?

NCT00002635 is currently completed. Last updated 24 July 2013.

Last reviewed 2013-07-24 · How we verify

NCT00002635

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

PHASE II TRIAL OF 9-AMINOCAMPTOTHECIN IN ADVANCED CUTANEOUS T CELL LYMPHOMA

Completed Phase 2 Last updated 24 July 2013

What this trial tests

Phase 2 trial testing filgrastim in Lymphoma in 12 participants. Completed in 1 April 2000.

Timeline

1 May 1995

Primary endpoint
1 April 2000

1 April 2000

Quick facts

Lead sponsor	Yale University
Phase	Phase 2
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Primary purpose	treatment
Enrollment	12
Start date	1 May 1995
Primary completion	1 April 2000
Estimated completion	1 April 2000
Sites	3 locations across United States

Drugs / interventions tested

filgrastim — full drug profile →
aminocamptothecin — full drug profile →

Conditions studied

Lymphoma — all drugs for Lymphoma →

Sponsor

Yale University

Who can join

18 and older, any sex, with Lymphoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of aminocamptothecin in treating patients with advanced cutaneous T-cell lymphoma.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Phytochemical-Based Nanomedicine for Advanced Cancer Theranostics: Perspectives on Clinical Trials to Clinical Use.
Dhupal M, Chowdhury D. · · 2020 · cited 48× · PMID 33244231 · DOI 10.2147/ijn.s259628
Recent updates on nano-phyto-formulations based therapeutic intervention for cancer treatment.
Wahi A, Bishnoi M, Raina N, Singh MA, et al · · 2023 · cited 20× · PMID 38188681 · DOI 10.32604/or.2023.042228

Verify or expand the search:

Other trials of filgrastim

Trials testing the same drug.

NCT06926751 — Telpegfilgrastim vs Filgrastim for Secondary Prevention of Chemotherapy-Induced Neutropenia in Pediatric Solid Tumors · Phase 2 · not yet recruiting
NCT04023669 — Evaluation of LY2606368 Therapy in Combination With Cyclophosphamide or Gemcitabine for Children and Adolescents With Re · Phase 1 · completed
NCT03434262 — SJDAWN: St. Jude Children's Research Hospital Phase 1 Study Evaluating Molecularly-Driven Doublet Therapies for Children · Phase 1 · completed
NCT02029638 — BMT and High Dose Post-Transplant Cyclophosphamide for Chimerism Induction and Renal Allograft Tolerance · Phase 2 · terminated
NCT01707004 — Decitabine and Total-Body Irradiation Followed By Donor Bone Marrow Transplant and Cyclophosphamide in Treating Patients · Phase 2 · completed

Other recruiting trials for Lymphoma

Currently open trials in the same condition.

NCT07302347 — A Study of Pembrolizumab in Japanese Pediatric Participants With Solid Tumors or Lymphomas and Japanese Adult Participan · Phase 1, PHASE2 · recruiting
NCT07566377 — Cord Blood Transplantation in Children and Young Adults With Blood Cancer · Phase 2 · recruiting
NCT06856226 — Natural History Study to Determine Drug Metabolism Phenotype and Appropriate Germline Source DNA in Patients Undergoing · recruiting
NCT07226934 — An AI-Generated, Personalized Question Prompt List Intervention for Patients With Hematologic Cancers · NA · recruiting
NCT07138547 — GSL Synthetase Inhibitor Eliglustat Combined With CD30 Target Immunotherapy for the Treatment of of CD30+ Lymphoma · Phase 1, PHASE2 · recruiting

Other Yale University trials

Trials by the same sponsor.

NCT06900998 — Pilot Study: Effects of Nimodipine on Alcohol Drinking · Phase 2 · not yet recruiting
NCT04910984 — Developing a Chatbot to Promote HIV Testing · NA · not yet recruiting
NCT07458087 — Accuracy of the Accuro 3S · NA · not yet recruiting
NCT07398404 — A Multiple Health Behavior Change (MHBC) Intervention for Weight Loss and Smoking Cessation for Pre-Bariatric Surgery Pa · Phase 1, PHASE2 · not yet recruiting
NCT07305324 — Improving Liver Fibrosis Diagnosis in Primary Care Using FibroX AI · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT00002635 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Yale University
Last refreshed: 24 July 2013

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00002635.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing